tetano
Editor, Senior Moderator
Cureus
. 2022 Jul 24;14(7):e27213.
doi: 10.7759/cureus.27213. eCollection 2022 Jul.
New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine
Ana Abicic[SUP] 1 [/SUP], Barbara Sitas[SUP] 2 [/SUP], Ivan Adamec[SUP] 2 3 [/SUP], Ervina Bilic[SUP] 2 3 [/SUP], Mario Habek[SUP] 2 3 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) vaccines have been reported as possible triggers of the production of antibodies pathogenic to the peripheral nerve and neuromuscular junction. We report on a patient who experienced vertical diplopia three weeks after the booster dose of the Pfizer-BioNTech vaccine (Comirnaty®). The diagnosis of myasthenia gravis (MG) was established based on highly positive antibodies to the nicotinic acetylcholine receptor (nAChR). Treatment with pyridostigmine and prednisone was started with gradually raising doses. On a follow-up exam two months after treatment initiation, clinical improvement was noted with an almost normal bulbomotor examination. The occurrence of diplopia following COVID-19 vaccination should raise suspicion of new-onset ocular MG and testing for anti-nAChR antibodies is advised.
Keywords: autoimmune diseases; bnt162 vaccine; covid-19 vaccines; diplopia; myasthenia gravis.
. 2022 Jul 24;14(7):e27213.
doi: 10.7759/cureus.27213. eCollection 2022 Jul.
New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine
Ana Abicic[SUP] 1 [/SUP], Barbara Sitas[SUP] 2 [/SUP], Ivan Adamec[SUP] 2 3 [/SUP], Ervina Bilic[SUP] 2 3 [/SUP], Mario Habek[SUP] 2 3 [/SUP]
Affiliations
- PMID: 36035038
- PMCID: PMC9399320
- DOI: 10.7759/cureus.27213
Abstract
Coronavirus disease 2019 (COVID-19) vaccines have been reported as possible triggers of the production of antibodies pathogenic to the peripheral nerve and neuromuscular junction. We report on a patient who experienced vertical diplopia three weeks after the booster dose of the Pfizer-BioNTech vaccine (Comirnaty®). The diagnosis of myasthenia gravis (MG) was established based on highly positive antibodies to the nicotinic acetylcholine receptor (nAChR). Treatment with pyridostigmine and prednisone was started with gradually raising doses. On a follow-up exam two months after treatment initiation, clinical improvement was noted with an almost normal bulbomotor examination. The occurrence of diplopia following COVID-19 vaccination should raise suspicion of new-onset ocular MG and testing for anti-nAChR antibodies is advised.
Keywords: autoimmune diseases; bnt162 vaccine; covid-19 vaccines; diplopia; myasthenia gravis.